Skip to main content
. 2021 Feb 4;11:614488. doi: 10.3389/fimmu.2020.614488

Figure 2.

Figure 2

Overall survival (OS) and disease-free survival (DFS) rates for all patients (A, D), the myeloid cohort (B, E), and the lymphoid cohort (C, F), based on the variation (D, decreased; U, unchanged; I, increased) in their iKIR-HLA C pair post-transplantation.